請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40172完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳秀熙(Hsiu-Hsi Chen) | |
| dc.contributor.author | Deng-Huang Su | en |
| dc.contributor.author | 蘇登煌 | zh_TW |
| dc.date.accessioned | 2021-06-14T16:42:08Z | - |
| dc.date.available | 2018-07-31 | |
| dc.date.copyright | 2008-09-11 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-07-31 | |
| dc.identifier.citation | 1. Cappelli C, Castellano M, Pirola I, Gandossi E, De ME, Cumetti D, Agosti B, Rosei EA. Thyroid nodule shape suggests malignancy. Eur J Endocrinol 2006;155:27-31.
2. Al-Brahim N, Asa SL. Papillary thyroid carcinoma: an overview. Arch Pathol Lab Med 2006;130:1057-62. 3. Hoang JK, Lee WK, Lee M, Johnson D, Farrell S. US Features of thyroid malignancy: pearls and pitfalls. Radiographics 2007;27:847-60. 4. Carpi A, Nicolini A, Casara D, Rubello D, Rosa PM. Nonpalpable thyroid carcinoma: clinical controversies on preoperative selection. Am J Clin Oncol 2003;26:232-35. 5. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD, Jr. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141:259-77. 6. Negri E, Ron E, Franceschi S, Dal ML, Mark SD, Preston-Martin S, McTiernan A, Kolonel L, Kleinerman R, Land C, Jin F, Wingren G, Galanti MR, Hallquist A, Glattre E, Lund E, Levi F, Linos D, Braga C, La VC. A pooled analysis of case-control studies of thyroid cancer. I. Methods. Cancer Causes Control 1999;10:131-42. 7. Negri E, Dal ML, Ron E, La VC, Mark SD, Preston-Martin S, McTiernan A, Kolonel L, Yoshimoto Y, Jin F, Wingren G, Rosaria GM, Hardell L, Glattre E, Lund E, Levi F, Linos D, Braga C, Franceschi S. A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control 1999;10:143-55. 8. La VC, Ron E, Franceschi S, Dal ML, Mark SD, Chatenoud L, Braga C, Preston-Martin S, McTiernan A, Kolonel L, Mabuchi K, Jin F, Wingren G, Galanti MR, Hallquist A, Lund E, Levi F, Linos D, Negri E. A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 1999;10:157-66. 9. Franceschi S, Preston-Martin S, Dal ML, Negri E, La VC, Mack WJ, McTiernan A, Kolonel L, Mark SD, Mabuchi K, Jin F, Wingren G, Galanti R, Hallquist A, Glattre E, Lund E, Levi F, Linos D, Ron E. A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 1999;10:583-95. 10. Dal ML, La VC, Franceschi S, Preston-Martin S, Ron E, Levi F, Mack W, Mark SD, McTiernan A, Kolonel L, Mabuchi K, Jin F, Wingren G, Galanti MR, Hallquist A, Glattre E, Lund E, Linos D, Negri E. A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control 2000;11:137-44. 11. Bosetti C, Kolonel L, Negri E, Ron E, Franceschi S, Dal ML, Galanti MR, Mark SD, Preston-Martin S, McTiernan A, Land C, Jin F, Wingren G, Hallquist A, Glattre E, Lund E, Levi F, Linos D, La VC. A pooled analysis of case-control studies of thyroid cancer. VI. Fish and shellfish consumption. Cancer Causes Control 2001;12:375-82. 12. Bosetti C, Negri E, Kolonel L, Ron E, Franceschi S, Preston-Martin S, McTiernan A, Dal ML, Mark SD, Mabuchi K, Land C, Jin F, Wingren G, Galanti MR, Hallquist A, Glattre E, Lund E, Levi F, Linos D, La VC. A pooled analysis of case-control studies of thyroid cancer. VII. Cruciferous and other vegetables (International). Cancer Causes Control 2002;13:765-75. 13. Mack WJ, Preston-Martin S, Dal ML, Galanti R, Xiang M, Franceschi S, Hallquist A, Jin F, Kolonel L, La VC, Levi F, Linos A, Lund E, McTiernan A, Mabuchi K, Negri E, Wingren G, Ron E. A pooled analysis of case-control studies of thyroid cancer: cigarette smoking and consumption of alcohol, coffee, and tea. Cancer Causes Control 2003;14:773-85. 14. Kim EK, Park CS, Chung WY, Oh KK, Kim DI, Lee JT, Yoo HS. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol 2002;178:687-91. 15. Rago T, Vitti P, Chiovato L, Mazzeo S, De LA, Miccoli P, Viacava P, Bogazzi F, Martino E, Pinchera A. Role of conventional ultrasonography and color flow-doppler sonography in predicting malignancy in 'cold' thyroid nodules. Eur J Endocrinol 1998;138:41-46. 16. Peccin S, de Castsro JA, Furlanetto TW, Furtado AP, Brasil BA, Czepielewski MA. Ultrasonography: is it useful in the diagnosis of cancer in thyroid nodules? J Endocrinol Invest 2002;25:39-43. 17. Cappelli C, Pirola I, Cumetti D, Micheletti L, Tironi A, Gandossi E, Martino E, Cherubini L, Agosti B, Castellano M, Mattanza C, Rosei EA. Is the anteroposterior and transverse diameter ratio of nonpalpable thyroid nodules a sonographic criteria for recommending fine-needle aspiration cytology? Clin Endocrinol (Oxf) 2005;63:689-93. 18. Lu C, Chang TC, Hsiao YL, Kuo MS. Ultrasonographic findings of papillary thyroid carcinoma and their relation to pathologic changes. J Formos Med Assoc 1994;93:933-38. 19. Iannuccilli JD, Cronan JJ, Monchik JM. Risk for malignancy of thyroid nodules as assessed by sonographic criteria: the need for biopsy. J Ultrasound Med 2004;23:1455-64. 20. Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD, Jr., Larsen PR, Marqusee E, Alexander EK. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab 2006;91:3411-17. 21. Moon HG, Jung EJ, Park ST, Ha WS, Choi SK, Hong SC, Lee YJ, Joo YT, Jeong CY, Choi DS, Ryoo JW. Role of ultrasonography in predicting malignancy in patients with thyroid nodules. World J Surg 2007;31:1410-1416. 22. Koike E, Yamashita H, Noguchi S, Murakami T, Ohshima A, Maruta J, Kawamoto H, Yamashita H. Effect of combining ultrasonography and ultrasound-guided fine-needle aspiration biopsy findings for the diagnosis of thyroid nodules. Eur J Surg 2001;167:656-61. 23. Kountakis SE, Skoulas IG, Maillard AA. The radiologic work-up in thyroid surgery: fine-needle biopsy versus scintigraphy and ultrasound. Ear Nose Throat J 2002;81:151-54. 24. Mikosch P, Gallowitsch HJ, Kresnik E, Jester J, Wurtz FG, Kerschbaumer K, Unterweger O, Dinges HP, Lind P. Value of ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in an endemic goitre area. Eur J Nucl Med 2000;27:62-69. 25. Hatada T, Okada K, Ishii H, Ichii S, Utsunomiya J. Evaluation of ultrasound-guided fine-needle aspiration biopsy for thyroid nodules. Am J Surg 1998;175:133-36. 26. Karstrup S, Balslev E, Juul N, Eskildsen PC, Baumbach L. US-guided fine needle aspiration versus coarse needle biopsy of thyroid nodules. Eur J Ultrasound 2001;13:1-5. 27. Tunca F, Giles Y, Salmaslioglu A, Poyanli A, Yilmazbayhan D, Terzioglu T, Tezelman S. The preoperative exclusion of thyroid carcinoma in multinodular goiter: Dynamic contrast-enhanced magnetic resonance imaging versus ultrasonography-guided fine-needle aspiration biopsy. Surgery 2007;142:992-1002. 28. Alexander EK, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, Marqusee E. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002;87:4924-27. 29. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005;237:794-800. 30. Lin JD, Huang BY, Weng HF, Jeng LB, Hsueh C. Thyroid ultrasonography with fine-needle aspiration cytology for the diagnosis of thyroid cancer. J Clin Ultrasound 1997;25:111-18. 31. Danese D, Sciacchitano S, Farsetti A, Andreoli M, Pontecorvi A. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid 1998;8:15-21. 32. Koike E, Noguchi S, Yamashita H, Murakami T, Ohshima A, Kawamoto H, Yamashita H. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg 2001;136:334-37. 33. Watters DA, Ahuja AT, Evans RM, Chick W, King WW, Metreweli C, Li AK. Role of ultrasound in the management of thyroid nodules. Am J Surg 1992;164:654-57. 34. Chung WY, Chang HS, Kim EK, Park CS. Ultrasonographic mass screening for thyroid carcinoma: a study in women scheduled to undergo a breast examination. Surg Today 2001;31:763-67. 35. Lee HK, Hur MH, Ahn SM. Diagnosis of occult thyroid carcinoma by ultrasonography. Yonsei Med J 2003;44:1040-1044. 36. Kim WB, Han SM, Kim TY, Nam-Goong IS, Gong G, Lee HK, Hong SJ, Shong YK. Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf) 2004;60:719-25. 37. Kurata S, Ishibashi M, Hiromatsu Y, Kaida H, Miyake I, Uchida M, Hayabuchi N. Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: prevalence of thyroid cancer and Hashimoto's thyroiditis. Ann Nucl Med 2007;21:325-30. 38. Chu QD, Connor MS, Lilien DL, Johnson LW, Turnage RH, Li BD. Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 2006;72:272-75. 39. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794-804. 40. Lo CY, Lorentz TG, Wan KY. Follicular carcinoma of the thyroid gland in Hong Kong Chinese. Br J Surg 1995;82:1095-97. 41. Besic N, Auersperg M, Golouh R. Prognostic factors in follicular carcinoma of the thyroid--a multivariate survival analysis. Eur J Surg Oncol 1999;25:599-605. 42. Mueller-Gaertner HW, Brzac HT, Rehpenning W. Prognostic indices for tumor relapse and tumor mortality in follicular thyroid carcinoma. Cancer 1991;67:1903-11. 43. Lerch H, Schober O, Kuwert T, Saur HB. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997;15:2067-75. 44. Hamming JF, Van d, V, Goslings BM, Schelfhout LJ, Fleuren GJ, Hermans J, Zwaveling A. Prognosis and morbidity after total thyroidectomy for papillary, follicular and medullary thyroid cancer. Eur J Cancer Clin Oncol 1989;25:1317-23. 45. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg 2003;128:115-23. 46. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 2007;245:366-78. 47. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1998;133:419-25. 48. Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol 1983;118:865-86. 49. Chen TH, Yen MF, Shiu MN, Tung TH, Wu HM. Stochastic model for non-standard case-cohort design. Stat Med 2004;23:633-47. 50. Wu HM, Yen MF, Chen TH. SAS macro program for non-homogeneous Markov process in modeling multi-state disease progression. Comput Methods Programs Biomed 2004;75:95-105. 51. Coburn MC, Wanebo HJ. Age correlates with increased frequency of high risk factors in elderly patients with thyroid cancer. Am J Surg 1995;170:471-75. 52. Krausz Y, Uziely B, Karger H, Isacson R, Catane R, Glaser B. Recurrence-associated mortality in patients with differentiated thyroid carcinoma. J Surg Oncol 1993;52:164-68. 53. Demeter JG, De Jong SA, Lawrence AM, Paloyan E. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991;110:956-61. 54. Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H, Niederle B. Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg 1999;384:284-93. 55. Lo CY, Lam KY, Wan KY. Anaplastic carcinoma of the thyroid. Am J Surg 1999;177:337-39. 56. Clark JR, Lai P, Hall F, Borglund A, Eski S, Freeman JL. Variables predicting distant metastases in thyroid cancer. Laryngoscope 2005;115:661-67. 57. Borson-Chazot F, Causeret S, Lifante JC, Augros M, Berger N, Peix JL. Predictive factors for recurrence from a series of 74 children and adolescents with differentiated thyroid cancer. World J Surg 2004;28:1088-92. 58. Yamashita H, Noguchi S, Yamashita H, Murakami N, Watanabe S, Uchino S, Kawamoto H, Toda M, Nakayama I. Changing trends and prognoses for patients with papillary thyroid cancer. Arch Surg 1998;133:1058-65. 59. Grigsby PW, Reddy RM, Moley JF, Hall BL. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment. Surgery 2006;140:1043-47. 60. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-76. 61. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007;92:28-38. 62. Leenhardt L, Menegaux F, Franc B, Delbot T, Mansour G, Hoang C, Guillausseau C, Aurengo H, Le GD, Turpin G, Aurengo A, Chigot JP, Hejblum G. Selection of patients with solitary thyroid nodules for operation. Eur J Surg 2002;168:236-41. 63. Katagiri M, Harada T, Kiyono T. Diagnosis of thyroid carcinoma by ultrasonic examination: comparison with diagnosis by fine needle aspiration cytology. Thyroidology 1994;6:21-26. 64. Tae HJ, Lim DJ, Baek KH, Park WC, Lee YS, Choi JE, Lee JM, Kang MI, Cha BY, Son HY, Lee KW, Kang SK. Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules. Thyroid 2007;17:461-66. 65. Huang BY, Lin JD, Huang MJ, Huang HS, Wong PW, Lee N. [Diagnostic value of ultrasonography and aspiration cytology for thyroid nodules]. Taiwan Yi Xue Hui Za Zhi 1988;87:978-83. 66. Tezelman S, Giles Y, Tunca F, Gok K, Poyanli A, Salmaslioglu A, Terzioglu T. Diagnostic value of dynamic contrast medium enhanced magnetic resonance imaging in preoperative detection of thyroid carcinoma. Arch Surg 2007;142:1036-41. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40172 | - |
| dc.description.abstract | 研究背景與目的
甲狀腺癌一直是內分泌科中最重要的癌症，其發生率在近年來也是一直在增加，但國內對這個主題仍缺乏重視。雖然大部份的甲狀腺癌預後都很好，但仍有一部份的患者會面臨死亡，什麼因子與其存活有關呢?過去一直都是用存活分析來處理這個問題，有無其他的方法可以解決這個問題呢?而甲狀腺超音波用在甲狀腺癌的偵測上，一直沒有確鑿的證據來證明其對甲狀腺癌患者的存活有助益，是否可以其他方法嘗試來解決這個問題?本論文的目的在於建構一個甲狀腺癌的世代，透過這個世代的建立來建構甲狀腺癌的自然史及多階段的治療史，以了解不同的因子作用，並以不同模式之間的比較來估計使用甲狀腺超音波在甲狀腺癌高危險群的篩檢其可能之功效。 研究方法 本研究為以醫院為背景的回溯性研究，採類個案世代研究(non-standard case-cohort design)的方法進行，將西元1985年後在台大醫院進行甲狀腺超音波檢查的民眾及甲狀腺癌患者(依死亡及存活分類)，依不同比例抽樣來選取個案，使用馬可夫多階段模式構成甲狀腺癌多階段模式。先建構多階段自然史模式，並運用單一變數分析及多變數分析了解各因子是否為有影響之因子及其參數。再建構多階段治療史模式，並運用單一變數分析及多變數分析了解各因子的作用，並估算使用甲狀腺超音波的介入對於模式的影響。 主要研究結果 在甲狀腺癌自然史的分析，其發生率主要還是受到性別和年齡的影響，並且存在著性別和年齡的交互作用；當甲狀腺癌在無法以手術治愈的過程中，其相關因子為診斷時年齡大於60歲、腫瘤大於1公分以上、有侵犯甲狀腺以外的組織及甲狀腺癌組織分類(濾泡癌和髓質癌)。另在治療後轉成無法以手術治愈的分化甲狀腺癌的過程中，診斷時年齡大於40歲以上、腫瘤大於1公分以上及侵犯甲狀腺以外組織為此階段之預後因子。當其轉成無法以手術治愈的分化甲狀腺癌後而死於此癌症的過程中，診斷時年齡大於40歲以上、濾泡癌和髓質癌為其預後因子。當轉變成未分化癌或分化不良的甲狀腺癌之過程中，有男性、診斷時年齡大於60歲和侵犯甲狀腺以外組織等預後因子。另在未分化癌或分化不良的甲狀腺癌死於甲狀腺癌的過程中，診斷時其年齡介於40-60歲為預後因子。 甲狀腺超音波檢查對於預防甲狀腺癌是否進展至較差的階段有13%(95%CI: -25%~41%)的功效，其主要的功效是在預防分化良好的甲狀腺癌變成未分化癌或分化不良的甲狀腺癌。 結論 本研究應用類個案世代研究於甲狀腺癌自然史及預後因子之探討，為有效又具經濟之研究設計，除可節省大量的時間和人力，而之所建構之甲狀腺癌多階段模式也確實可找出預後因子及評估甲狀腺超音波介入的功效，而將甲狀腺癌用多階段模式來了解其自然病程，目前是沒有文獻採類似的方法，本研究是最先採用此模式之研究。 | zh_TW |
| dc.description.abstract | Background and purpose
The incidence rate of thyroid cancer has been increasing in recent years. While the prognosis of thyroid cancer is good, but there are still a fraction of the patients that eventually have poor prognosis. Thyroid ultrasound has been adopted for early detection of thyroid cancer, but the evidence is elusive. The aims of this study were to build a cohort of thyroid cancer and construct the multi-state natural disease history and multi-state treatment history of thyroid cancer to assess how natural progression of thyroid cancer evolves and how putative personal attributes and clinical attributes affect its natural course. Efficacy of thyroid ultrasound was further estimated by using two kinds of stochastic process. Methods This study was based on a hospital-based, non-standard case-cohort design. The cohort was composed of the patients with thyroid ultrasound in National Taiwan University Hospital after1985 and patients with thyroid cancers. The cases were randomly selected by different sampling ratios according to the status of thyroid cancer and survival. Multi-state Markov models of natural diseaase history and treatment history of thyroid cancer were constructed. Bayesian inversion tailor for non-standard case-cohort design was applied to identify significant factors responsible for each transition. The estimate of efficacy of thyroid ultrasound was done between the comparisons of different models. . Main findings In the natural disease history of thyroid cancer, the annual incidence rate from free of thyroid cance to ETC (echo-detectable thyroid cancer) was mainly affected by gender and age. Factors responsible for the transition between ETC and incurable stage included age of diagnosis, tumor size larger than 1 cm, the invasion of the extrathyroidal tissue, and the classification of thyroid cancer (medullary and follicular carcinoma). The transition between ETC and incurable differentiated thyroid cancer after treatment was affected by age of diagnosis, tumor size larger than 1 cm, and the invasion of the extrathyroidal tissue. Prognostic factors related to death from incurable differentiated thyroid cancer included age of diagnosis, medullary carcinoma and follicular carcinoma. Significant relevant factors pertaining to an anaplastic carcinoma or poorly differentiated thyroid cancer were male, age of diagnosis older more than 60 years old and the invasion of the extrathyroidal tissue. Significant factor for the transition anaplastic cancer or poorly differentiated thyroid cancer to death was was age of diagnosis between 40-60 years old. The efficacy of the ultrasound was 13% (95%CI:-25 -41%) in the arresting the procession from ETC to incurable thyroid cancer, and the efficacy was mainly in the prevention of well-differentiated thyroid cancer into anaplastic cancer or poorly differentiated thyroid cancer. Conclusion Non-standard case-cohort study together with a multi-state model is efficient in elucidating the natural history of thyroid cancer, significant factors related to natural course, and the efficacy. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-14T16:42:08Z (GMT). No. of bitstreams: 1 ntu-97-R95846002-1.pdf: 1727259 bytes, checksum: b2c4fca9663d68376f6f36654ed7a66c (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 目錄
中文摘要 I Abstract. III 目錄 ..........…………………………………………………………………………...VI 表目錄………………………………………………………………………………VIII 圖目錄……………………………………………………………………….………..X 第一章 研究動機和目的 1 第二章 文獻回顧 3 第一節 甲狀腺癌現狀 3 第二節 甲狀腺癌的危險因子 4 第三節 甲狀腺癌的診斷工具：甲狀腺超音波和細胞學檢查 5 第四節 甲狀腺癌的篩檢 7 第五節 甲狀腺癌的預後因子 8 第六節 甲狀腺癌和馬可夫（Markov）模式 11 第三章 材料與方法 13 第一節 研究世代 13 第二節 抽樣樣本 13 第三節 資料收集 14 第四節 甲狀腺癌依超音波之階段分類 14 第五節 甲狀腺癌多階段自然史模式 15 第六節 甲狀腺癌多階段治療史模式 16 第七節 統計方法 17 第四章 結果 20 第一節 基本人口資料 20 第二節 甲狀腺癌病理結果 22 第三節 死因分析 23 第四節 甲狀腺癌自然史及相關因子 23 第五節 甲狀腺癌治療後之多階段疾病死亡模式及相關因子 28 第七節 甲狀腺癌自然史及治療後之多階段疾病死亡模式之累積風險圖 37 第五章 討論 39 第六章 結論 46 參考文獻 79 附錄 英文縮寫中英對照表.......................................................................................91 | |
| dc.language.iso | zh-TW | |
| dc.subject | 甲狀腺超音波 | zh_TW |
| dc.subject | 甲狀腺癌 | zh_TW |
| dc.subject | 預後 | zh_TW |
| dc.subject | 馬可夫多階段模式 | zh_TW |
| dc.subject | 個案世代研究 | zh_TW |
| dc.subject | 甲狀腺癌自然疾病史 | zh_TW |
| dc.subject | Thyroid ultrasound | en |
| dc.subject | Thyroid cancer natural disease history | en |
| dc.subject | Case cohort study | en |
| dc.subject | Markov multi-state model | en |
| dc.subject | Thyroid cancer | en |
| dc.subject | Prognosis | en |
| dc.title | 甲狀腺癌自然疾病史和預後之類病例世代研究 | zh_TW |
| dc.title | A Non-standard Case-cohort Study for the Disease Natural History and Prognosis of Thyroid Cancer | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 張天鈞(Tien-Chun Chang) | |
| dc.contributor.oralexamcommittee | 張淑惠,張慶忠,潘信良 | |
| dc.subject.keyword | 甲狀腺癌,預後,甲狀腺超音波,馬可夫多階段模式,個案世代研究,甲狀腺癌自然疾病史, | zh_TW |
| dc.subject.keyword | Thyroid cancer,Prognosis,Thyroid ultrasound,Markov multi-state model,Case cohort study,Thyroid cancer natural disease history, | en |
| dc.relation.page | 90 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2008-08-01 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 預防醫學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf 未授權公開取用 | 1.69 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。